LungLife AI shareholders approve AIM delisting and new deal

Published 20/05/2025, 17:18
LungLife AI shareholders approve AIM delisting and new deal

LONDON - LungLife AI, Inc. (AIM:LLAI), a company specializing in clinical diagnostic solutions for lung cancer, announced today that its shareholders have approved two key resolutions during a Special Meeting. The first resolution authorizes the cancellation of the company’s shares from trading on the AIM market, and the second approves an exclusive license and distribution agreement with Circulogene Theranostics, Inc.

The proxy votes showed overwhelming support for both resolutions, with 95.2% in favor of delisting from AIM and a unanimous vote for the agreement with Circulogene Theranostics. The cancellation of the Common Shares from AIM is scheduled for 7:00 a.m. on May 29, 2025, making May 28 the last day of trading for the company’s shares on the market.

The authorization of the transaction with Circulogene Theranostics paves the way for LungLife AI to proceed with the completion of the agreement. The company is currently coordinating with relevant stakeholders to obtain the necessary consents for completion, which is anticipated to occur in the second quarter of 2025, following the AIM delisting date.

The details of both the delisting and the exclusive license and distribution agreement were initially provided in a company announcement and a circular published on April 29, 2025. These documents are accessible on LungLife AI’s website for those seeking further information.

This move comes as part of LungLife AI’s strategic initiatives to realign its business operations and partnerships. The company’s focus remains on advancing diagnostic solutions for lung cancer, a leading cause of cancer-related deaths worldwide.

The information presented in this article is based on a press release statement from LungLife AI, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.